Locanabio is pioneering a new class of targeted therapies that specifically corrects dysfunctional RNA, the root cause of many devastating genetic diseases. By combining the specificity of RNA-binding proteins with the durable effect of a one-time gene therapy, we can address the underlying RNA defects in patients suffering from rare neuromuscular, neurodegenerative and retinal diseases.